Weekly Clinical Updates

Clinical assessment of confirmed human monkeypox virus cases in Spain | Monkeypox Virus Infection across 16 Countries | Clinical characteristics of ambulatory and hospitalized patients with monkeypox | Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection | Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years | Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age | Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater | Human-to-human transmission of monkeypox virus | What to Do If You Were Exposed to COVID-19 and its Isolation and Precautions for People with COVID-19 | Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations | Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment

Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 | Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 | Profiling post-COVID syndrome across different variants of SARS-CoV-2 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects | Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir

Viral and Symptom Rebound in Untreated COVID-19 Infection | Cognitive Impairment 13 Months After Hospitalization for COVID-19 | Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients | Extended Remdesivir Infusion for Persistent COVID-19 Infection | Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial and updated meta-analysis

Symptoms and risk factors for long COVID in non-hospitalized adults | Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study

Children and COVID-19: State level Data Report | SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages | CDC Recommends Novavax’s COVID-19 Vaccine for Adults | Paxlovid in patients who are immunocompromised and hospitalized with SARS-CoV-2 infection | Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial